Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 + trastuzumab plus chemotherapy in first-line HER2-positive metastatic pancreatic ductal adenocarcinoma
ChiCTR2500109825Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hlx22 in pancreatic adenocarcinoma (PDAC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate (ORR). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
hlx22
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500109825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109825.